CAMBRIDGE, Mass., Aug. 25, 2022 -- Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced...
Eric Linsley to speak at CED's Biotech Forum: "How Early is Too Early?" in RTP, NC
News | 04. 28. 2008
